Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Longitudinal Alterations in Sleep EEG Biomarkers of Memory Consolidation in Middle-Aged and Older Adults.

bioRxiv : the preprint server for biology·2026
Same author

Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta-analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Feasibility and validity of using self-collected capillary blood using Tasso+ for measuring Alzheimer's Disease plasma-based biomarkers among underrepresented populations.

medRxiv : the preprint server for health sciences·2026
Same author

Longitudinal, Intra-Individual Stability of Untargeted Plasma and Cerebrospinal Fluid Metabolites.

Metabolites·2026
Same author

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Ramiro Eduardo Rea Reyes1, Rachael E Wilson2, Julie E Oomens3

  • 1Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

较高的体重与较低的血pTau217水平有关,这是阿尔茨海默病 (AD) 的关键生物标志物. 根据体量进行调整,可以通过血液检测改善早期AD检测.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经退行性疾病的神经退行性疾病
  • 发现生物标志物的发现.
  • 阿尔茨海默病的诊断阿尔茨海默病的诊断.

背景情况:

  • 血pTau217是阿尔茨海默病 (AD) 中粉样蛋白病理学的验证生物标志物.
  • 诸如体重 (体量) 等因素可能会影响pTau217测量的准确性.
  • 了解肥胖的影响对于早期阿尔茨海默病检测研究至关重要.

研究的目的:

  • 为了研究体积对血pTau217度的影响.
  • 评估肥胖对其他与阿尔茨海默病相关的血液生物标志物的影响.
  • 用 pTau217.7 来确定体量对粉样蛋白阳性的分类准确性的影响.

主要方法:

  • 对阿尔茨海默病研究队伍中746名参与者的纵向血样本的分析.
  • 血生物标志物的测量包括pTau217,GFAP,NfL,Aβ40和Aβ42.
  • 使用混合玛回归来建模生物标记水平,包括年龄,体量,APOEε4载体和性别.

主要成果:

  • 增加的体量与血pTau217水平在粉样蛋白蓄积体和非蓄积体中降低了4 - 5%.
  • 由于肥胖而导致的pTau217的减少相当于大约3.25年延迟达到肥胖个体的诊断值.
  • 对于GFAP和NfL观察到类似的减少,但对于Aβ42/Aβ40比率没有.

结论:

  • 肥胖显著影响了AD关键生物标志物的血水平,包括pTau217,GFAP和NfL.
  • 在分析中考虑身体质量可能会提高基于血的AD生物标志物测量的精度.
  • 根据体量进行调整可以显著改善使用血液检测早期检测阿尔茨海默病的情况.